News About: R&D
Government urged to boost local pharmaceutical industry
The government needs to encourage pharmaceutical firms to develop more effective and cheaper drugs, strengthening the competitiveness of the country's pharmaceutical industry, through elimination of unclear license sy...
8.2 trillion won to set aside for state R&D spending next year
The National Science & Technology Council said that the government is planning to spend around 8.2 trillion won on state-funded R& D projects next year.
The funding plan was set by the presidential science and tech...
ViroMed’s VM202 emerging as blockbuster medicine
ViroMed said on November 28 that the phase I study results of VM202, a gene-based medicine for cardiovascular disease (CVD) were presented in the Seoul National University Hospital’s clinical center.
The clinical r...
Government to spend 3.8 bn over R&D of Ilyang’s leukemia medicine
The government plans to earmark 3.8 billion won for Ilyang Pharm’s new leukemia treatment candidate IY5511 that has the potential to be used as a drug, it was announced on November 24.
The Korea Health Industry Dev...
LG Life Sciences joins up with Seoul National University over cell therapy researchLG Life Sciences says it has signed with Seoul National University’s Innovative Research Institute for Cell Therapy (IRICT) to develop cell-based therapeutic agents.
“The fie...
|
Lilly Korea launches Byetta injections
Lilly Korea has launched Byetta (exenatide), the first in a new class of medications specifically created to treat type 2 diabetes.
Byetta (5 mcg exenatide or 10 mcg exenatide) is indicated as an add-on therapy for...
Duel in cold drink marketThe duel among cold drink makers has reached another round on the local market.
Chong Kun Dang Pharmaceutical has recently launched its popular brand “Penzal” in the form of ...
|
Drug patent dispute to get fiercer
Patent dispute for pharmaceuticals will get fiercer as many Korean drug makers are rushing to introduce first generic versions of original brands whose patents are to be expired, with hope of acquiring large share of ...
Hanmi teams up with Kyungwon Medical over bone replacement products
Hanmi Pharm plans to sell a revolutionary bone substitute, PolyBone (calcium phosphate bone substitute) that regenerates bone after implantation and Optimum-S (bone cement) through a strategic alliance with Kyungwon M...
ViroMed to conduct phase II trial of VM202
ViroMed president Kim Sung-young said that she had a meeting with some of the US investigators and clinicians in New Orleans on November 8 in order to further evaluate the clinical benefit of VM202 through its planned...
